FROM: Sue Pope, RPh
Manager, Investigational Drug Service

TO: Robert Sandler, MD

CC: Shelby Dunivant

DATE: August 28, 2009

RE: IDS Protocol (P10-1173C) Curcumin Chemoprevention of Colorectal Neoplasia

Investigational Drug Services (IDS) has been contacted to provide pharmacy services for the above protocol. A pharmacist member of the IDS staff has reviewed the protocol and the protocol has been filed in the IDS pending file until notification is received from the principal investigator that the protocol is ready to screen patients.

Once IDS receives the notification that the protocol is actively screening for patients, a meeting will be scheduled with the study coordinator to review the specifics of the protocol and set a time-line for the first dispensation of clinical trial materials.

Should you require any additional information, please do not hesitate to contact me.
Please notify IDS six to eight weeks before you plan on randomizing the first study subject so that we may in-service all of the appropriate staff and template the study protocol orders.

The following items are required for an IRB submission letter from IDS:

1. A copy of the most recent protocol.
2. A completed IDS Request for Services form. The RFS form can be located by accessing the following Department of Pharmacy Link:

   http://intranet.unchealthcare.org/site/w3/pharmacy/services/investdrugs

In addition to the above paperwork, the following items (if applicable) are needed to finalize the protocol with IDS for dispensation of Clinical Trial Materials:

1. A copy or access to the Investigator's Brochure.
2. A copy of the FDA 1572 form or a list of authorized prescribers if a 1572 is not required.
3. A copy of the Pharmacy Manual and/or Sponsor provided Accountability Records.
4. A 98 account or University Grant number.
IDS Protocol Budget

Investigational Drug Services
Annual Fee for Services*

<table>
<thead>
<tr>
<th>Sponsored</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Sponsored</td>
<td>$2000.00</td>
</tr>
<tr>
<td>Investigator Initiated, Industry Sponsored</td>
<td>$1000.00</td>
</tr>
<tr>
<td>NIH/Gov/Foundation Sponsored</td>
<td>$1500.00</td>
</tr>
<tr>
<td>Investigator Initiated, No Sponsor</td>
<td>$500.00</td>
</tr>
</tbody>
</table>

*Per year, payable upon receipt of drug/study notebook completion and yearly thereafter.

Note: The section below should be filled out and signed by business administrator or person responsible for disbursement of funds, and returned to the Investigational Drug Service (mail or fax) before start of the study; if not returned, IDS is authorized to bill for its services based on this sheet as-is.

<table>
<thead>
<tr>
<th>Prepared By: Sue Pope, RPh</th>
<th>Name and address where invoices should be sent:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principal Investigator/ Business Administrator</td>
<td>Date:</td>
</tr>
<tr>
<td>Signature:</td>
<td></td>
</tr>
</tbody>
</table>

Account Number (University or Hospital)
Departmental Internal Tracking Number if applicable:

By signing this agreement the Investigational Drug Service agrees to provide the above services.

The Principal Investigator agrees to the following:
1. To provide a copy of or access to both the complete written protocol and the Investigator's Brochure
2. To provide full reimbursement for the above stated services
3. To provide a copy of the FDA form 1572 or a list of all authorized prescribers if a 1572 is not required
4. To provide a copy of the final IRB approval letter
5. To renegotiate the Service Agreement if (a) protocol revisions call for a change in the services needed from the Investigational Drug Service or (b) the cost of materials used in provided such services increases.